XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Net Loss Per Share (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2017
Earnings Per Share [Abstract] |
Schedule of Earnings Per Share, Basic and Diluted | The following tables reconcile the components of the numerator and denominator included in the calculations of diluted loss per share:
| Three Months Ended March 31,
| 2017 |  | 2016
Numerator |  |  |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (23,085,907 | ) |  | $ | (8,042,820 | )
Reflect adjustment for decrease in fair value of warrant liability | (116,477 | ) |  | — |
Numerator for use in diluted loss per share | $ | (23,202,384 | ) |  | $ | (8,042,820 | )
Denominator |  |  |
Weighted average number of common shares outstanding | 74,152,609 |  |  | 72,230,411 |
Effect of dilutive potential common shares | 148,275 |  |  | — |
Denominator for use in diluted loss per share | 74,300,884 |  |  | 72,230,411 |
Net loss per share, diluted | $ | (0.31 | ) |  | $ | (0.11 | )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following table summarizes potential common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect for the three months ended March 31, 2017 and 2016:
Common Stock Equivalents | 2017 |  | 2016
Options to purchase common stock | 7,841,669 |  |  | 7,135,624 |
Warrants to purchase common stock | — |  |  | 560,904 |
Restricted stock units | 1,376,893 |  |  | 732,668 |
Convertible preferred stock | 8,456 |  |  | 8,456 |
Total | 9,227,018 |  |  | 8,437,652 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration